Abstract
Biomarkers are of crucial importance in optimizing cancer therapies. In this edition of Clinical Cancer Research, Bañuelos and colleagues assess H2AX phosphorylation as a predictive biomarker of response to DNA damaging agents. We discuss these results as well as the impact that double strand break repair biomarkers may have in cancer therapy.
MeSH terms
-
Animals
-
Antineoplastic Agents / therapeutic use
-
Cell Line, Tumor
-
Cell Survival / drug effects
-
Cell Survival / radiation effects
-
Cisplatin / therapeutic use*
-
Combined Modality Therapy
-
DNA Breaks, Double-Stranded
-
DNA Repair*
-
Dose Fractionation, Radiation*
-
Flow Cytometry
-
Histones / biosynthesis*
-
Humans
-
Mice
-
Microscopy, Fluorescence
-
Models, Biological
-
Neoplasms, Experimental / metabolism
-
Neoplasms, Experimental / pathology
-
Neoplasms, Experimental / therapy*
-
Phosphorylation / drug effects
-
Phosphorylation / radiation effects
-
Xenograft Model Antitumor Assays
Substances
-
Antineoplastic Agents
-
H2AX protein, human
-
Histones
-
Cisplatin